Please Wait
Applying Filters...
menu
    • menu
    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Tuspetinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 175,273Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptose's Tuspetinib boosts AML treatment in Phase 1/2 Trial
    Aptose's Tuspetinib boosts AML treatment in Phase 1/2 Trial

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/18/3134929/35575/en/Aptose-Reports-Early-Data-Demonstrating-Tuspetinib-Improves-Standard-of-Care-Treatment-Across-Diverse-Populations-of-Newly-Diagnosed-AML-in-Phase-1-2-TUSCANY-Trial.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    Aptose Picks Ernst & Young Global Limited as New Auditor
    Aptose Picks Ernst & Young Global Limited as New Auditor

    01 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/01/3125714/35575/en/Aptose-Selects-Ernst-Young-Global-Limited-as-its-New-Independent-Auditor-and-Calls-Reconvened-Meeting-of-its-Shareholders.html

    GLOBENEWSWIRE
    01 Aug 2025
    Share Share
    Aptose Gets 2nd Loan from Hanmi for Tuspetinib in AML Therapy
    Aptose Gets 2nd Loan from Hanmi for Tuspetinib in AML Therapy

    15 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/15/3116053/35575/en/Aptose-Receives-Second-Advance-under-the-Loan-Agreement-with-Hanmi-Pharmaceutical-to-Continue-Development-of-Tuspetinib-in-Triplet-Therapy-for-AML.html

    GLOBENEWSWIRE
    15 Jul 2025
    Share Share
    clonoSEQ® MRD Testing Integrated into OncoEMR®
    clonoSEQ® MRD Testing Integrated into OncoEMR®

    01 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/01/3108232/0/en/Adaptive-Biotechnologies-and-Flatiron-Health-Announce-Integration-of-clonoSEQ-MRD-Testing-into-OncoEMR.html

    GLOBENEWSWIRE
    01 Jul 2025
    Share Share
    Aptose and Hanmi's New Loan Agreement for Tuspetinib in AML
    Aptose and Hanmi's New Loan Agreement for Tuspetinib in AML

    20 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/20/3102654/35575/en/Aptose-and-Hanmi-Enter-New-Loan-Agreement-to-Advance-Development-of-Tuspetinib-in-Triplet-Therapy-for-AML.html

    GLOBENEWSWIRE
    20 Jun 2025
    Share Share
    Aptose to Present Tuspetinib Data at 2025 EHA Congress
    Aptose to Present Tuspetinib Data at 2025 EHA Congress

    14 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/14/3081434/35575/en/Aptose-Selected-for-Prestigious-Oral-Presentation-of-Data-from-TUSCANY-Phase-1-2-Clinical-Trial-of-Tuspetinib-Triplet-Therapy-in-Newly-Diagnosed-AML-at-the-2025-EHA-Congress.html

    GLOBENEWSWIRE
    14 May 2025
    Share Share